File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy

TitleEpigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
Authors
KeywordsEpigenetic modification
Cancer
Epi-drugs
Combination strategy
Tumour microenvironment
Issue Date2020
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.molecular-cancer.com
Citation
Molecular Cancer, 2020, v. 19 n. 1, p. article no. 79 How to Cite?
AbstractEpigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response.
Descriptioneid_2-s2.0-85084107503
Persistent Identifierhttp://hdl.handle.net/10722/282546
ISSN
2023 Impact Factor: 27.7
2023 SCImago Journal Rankings: 8.222
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLU, Y-
dc.contributor.authorChan, Y-T-
dc.contributor.authorTan, H-Y-
dc.contributor.authorLi, S-
dc.contributor.authorWang, N-
dc.contributor.authorFeng, Y-
dc.date.accessioned2020-05-15T05:29:30Z-
dc.date.available2020-05-15T05:29:30Z-
dc.date.issued2020-
dc.identifier.citationMolecular Cancer, 2020, v. 19 n. 1, p. article no. 79-
dc.identifier.issn1476-4598-
dc.identifier.urihttp://hdl.handle.net/10722/282546-
dc.descriptioneid_2-s2.0-85084107503-
dc.description.abstractEpigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response.-
dc.languageeng-
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.molecular-cancer.com-
dc.relation.ispartofMolecular Cancer-
dc.rightsMolecular Cancer. Copyright © BioMed Central Ltd.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectEpigenetic modification-
dc.subjectCancer-
dc.subjectEpi-drugs-
dc.subjectCombination strategy-
dc.subjectTumour microenvironment-
dc.titleEpigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy-
dc.typeArticle-
dc.identifier.emailChan, Y-T: ecyt1@hku.hk-
dc.identifier.emailTan, H-Y: hyhtan@hku.hk-
dc.identifier.emailLi, S: lishaha@hku.hk-
dc.identifier.emailWang, N: ckwang@hku.hk-
dc.identifier.emailFeng, Y: yfeng@hku.hk-
dc.identifier.authorityWang, N=rp02075-
dc.identifier.authorityFeng, Y=rp00466-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s12943-020-01197-3-
dc.identifier.pmid32340605-
dc.identifier.pmcidPMC7184703-
dc.identifier.scopuseid_2-s2.0-85084107503-
dc.identifier.hkuros309972-
dc.identifier.volume19-
dc.identifier.issue1-
dc.identifier.spagearticle no. 79-
dc.identifier.epagearticle no. 79-
dc.identifier.isiWOS:000530432500001-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1476-4598-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats